Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of
paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients
with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well
tolerated therapies are needed to treat patients with relapsed and refractory lymphomas.
Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the
anticancer drug concentration in the tumor while reducing toxic effects in normal tissue and
may be an effective treatment for lymphoma.